CBD and Addiction Research

Plain-language summary

Cannabidiol (CBD) is a non-intoxicating cannabinoid that has been studied as a possible treatment for addiction. Researchers are interested because CBD appears to reduce anxiety and stress reactivity in animal models, and craving in humans is often triggered by stress and drug-associated cues.^[1]

The most-cited human result is a 2019 trial by Hurd and colleagues showing that 400–800 mg of oral CBD reduced cue-induced craving and anxiety in people with heroin use disorder for up to a week after dosing Weak / limited.^[2] This is a real, well-designed study — but it is one study, with 42 participants, measuring craving rather than long-term abstinence.

For most other substances (alcohol, cocaine, methamphetamine, nicotine), the human evidence is smaller, older, or contradictory. CBD is not an approved addiction treatment anywhere. The only FDA-approved CBD product is Epidiolex, for rare epilepsies.^[3]

This article is not medical advice. Addiction is a serious medical condition. Talk to a qualified clinician before changing any treatment.

What probably works (relatively speaking)

Honestly, nothing about CBD for addiction has reached the bar of "probably works" in the way that, say, buprenorphine for opioid use disorder has.

The strongest single result is Hurd et al. (2019): a double-blind, placebo-controlled trial in abstinent individuals with heroin use disorder. A single dose of CBD (400 mg or 800 mg) reduced craving and anxiety triggered by drug cues, with effects persisting at one week Weak / limited.^[2] This is the closest thing the field has to a clean positive signal.

Why "weak" and not "strong"? Because:

• n = 42
• The outcome was cue-induced craving, not sustained abstinence, overdose, or return to use
• It has not been independently replicated at scale
• Participants were already abstinent and not on agonist therapy

A promising signal is not proof. It justifies further trials, not clinical adoption.

What might work

Cannabis use disorder (CUD). A Phase 2a randomized trial by Freeman et al. (2020) tested 400 mg and 800 mg CBD daily in people trying to quit cannabis. Both doses reduced urinary THC-COOH levels and increased days of abstinence compared to placebo, while 200 mg was no better than placebo Weak / limited.^[4] Interesting result, single trial, needs replication.

Tobacco/nicotine. A small pilot (Morgan et al., 2013) found that ad-hoc inhaled CBD reduced cigarette consumption by about 40% over a week in dependent smokers Weak / limited.^[5] A follow-up study on cue reactivity was more mixed.^[6] The overall picture is suggestive but very underpowered.

Alcohol use disorder. Human data is essentially absent as of this writing. Preclinical rodent work shows CBD reduces alcohol self-administration and protects against alcohol-induced liver and brain damage Weak / limited.^[7] Rodents are not people, and "reduces drinking in rats" has a very poor track record of translating to human AUD treatments.

Anxiety and sleep as indirect targets. Some clinicians reason that if CBD reduces anxiety or improves sleep, it might indirectly support recovery. There is moderate evidence CBD reduces acute anxiety in experimental paradigms Weak / limited, but crossing from that to "helps people stay sober" is a big leap without direct trials.

What doesn't work or has weak evidence

• Over-the-counter CBD products at typical consumer doses (10–50 mg/day) have essentially no clinical evidence for addiction. Trials that showed effects used 400–800 mg/day of pharmaceutical-grade CBD [evidence:none for low-dose consumer products].
• CBD for stimulant use disorder (cocaine, methamphetamine). No adequately powered human trials support benefit No data.^[8]
• CBD as a stand-alone opioid replacement. There is no evidence CBD substitutes for or approaches the efficacy of methadone, buprenorphine, or extended-release naltrexone No data. These medications reduce mortality; CBD has not been shown to do so.^[9]
• "Full spectrum" or hemp-derived CBD tinctures for quitting anything. The dose, purity, and pharmacokinetics vary wildly across products, and none of the addiction trials used consumer-market products No data.^[10]
• Marketing claims that CBD is "non-addictive and treats addiction." The first half is largely true; the second half is running well ahead of the science.

What we don't know

• Whether CBD's short-term effect on craving translates into meaningful long-term outcomes like sustained abstinence, reduced overdose, or improved function.
• Optimal dose, duration, and formulation. Oral bioavailability of CBD is low and variable (roughly 6–19%), and food dramatically changes absorption.^[11]
• Whether effects hold up in people on agonist therapies (methadone, buprenorphine), which is how most opioid use disorder is actually treated.
• Long-term safety at 400–800 mg/day doses outside of epilepsy populations.
• Whether specific subpopulations (by genetics, sex, comorbid anxiety, PTSD) respond better.
• Drug–drug interactions with common addiction medications. CBD inhibits several CYP450 enzymes and can raise levels of drugs metabolized by CYP3A4, CYP2C19, and others.^[12]

Comparison with standard treatments

For opioid use disorder, the standard of care is medication for opioid use disorder (MOUD): buprenorphine, methadone, or extended-release naltrexone, combined with psychosocial support. These medications have decades of evidence and are associated with 50%+ reductions in all-cause mortality.^[9] CBD has no such evidence. It is not a substitute.

For tobacco use disorder, first-line treatments are varenicline, combination nicotine replacement therapy, and bupropion, all with robust RCT evidence.^[13] CBD has one small pilot.

For alcohol use disorder, naltrexone, acamprosate, and disulfiram are approved and supported by meta-analyses.^[14] CBD has essentially no human RCT data.

For cannabis use disorder, there is no FDA-approved medication, and behavioral therapies (CBT, contingency management, motivational enhancement) are first-line.^[15] This is the one area where CBD's Phase 2 data is competitive simply because nothing else is approved — but "competitive with nothing" is a low bar.

If CBD has a plausible near-term role, it is probably as an adjunct to standard care, especially for craving and anxiety, not as a replacement.

Risks and interactions

CBD is generally well-tolerated but not risk-free, particularly at the doses used in addiction trials.

• Liver enzyme elevations. Documented in Epidiolex trials, especially when combined with valproate.^[3]
• Drug–drug interactions. CBD inhibits CYP3A4, CYP2C19, and other enzymes, potentially raising levels of benzodiazepines, some SSRIs, warfarin, and other medications.^[12] Relevant for people in recovery who are often on multiple prescriptions.
• Sedation and fatigue, particularly at 400+ mg doses.
• Product quality. Independent testing repeatedly finds mislabeling, contamination, and unlabeled THC in consumer CBD products.^[10] Unlabeled THC can be a serious problem for anyone in recovery, on probation, or subject to drug testing.
• Cost. Pharmaceutical-grade CBD at trial doses is expensive; consumer products at those doses run hundreds of dollars a month with no guarantee of consistency.

This is not medical advice. If you or someone you love is struggling with a substance use disorder, contact a licensed clinician or, in the US, SAMHSA's National Helpline at 1-800-662-HELP (4357). Evidence-based treatments exist and save lives.

Sources

How this page was made

Related

• Cannabis Use Disorder — A real DSM-5 diagnosis affecting roughly 1 in 5 regular users, with modest but growing evi...